Galapagos NV and AbbVie have expanded their agreement in cystic fibrosis (CF) to reflect the successful expansion of their CF portfolio. The companies have agreed to increase the potential milestones to Galapagos for Phase 1 and 2 achievements, bringing the remaining total milestones in the CF alliance up to approximately $600 million, from $350 million. Other key collaboration terms remain in place: tiered royalty payments on net sales, ranging from mid-teens to 20 percent. Galapagos retains co...